Ayala Pharmaceuticals Inc (ADXS)

[Cycle1]

Re: AIM2SERVE

To end all speculative and innuendo on the status of AIM2SERV the Company clearly disclosed in the 10K filing the following. This will not be a value driver in the present. Fact is Fact.


In June 2019, the Company announced the closing of its AIM2CERV Phase 3 clinical trial with axalimogene filolisbac (AXAL) in high-risk
locally advanced cervical cancer. Company estimates showed that the remaining cost to complete the AIM2CERV trial ranged from $80 million to $90 million, and initial efficacy data was not anticipated for at least three years. Therefore, results from the clinical trial were not the basis for the decision to close the study, nor was safety as the trial recently underwent its third Independent Data Monitoring Committee (IDMC) review with no safety issues noted. The Company has unblinded the AIM2CERV clinical data generated to date and currently has no plans to present it at any medical conference as the data set is incomplete and inconclusive.

If ADXS can move and prove out what they have today (ie HOT construct in Combo Therapy) in some meaningful way (soon) then there is a chance to it can drive value forward.

As an observer of posts to his board rhetoric runs amuck!

And with that I do hope the present vector of the HOT/NEO demonstrates merit.